Safety and Efficacy of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration
Trial ID or NCT#
NCT02462486
Status
RECRUITING
Purpose
This is a safety and efficacy study of abicipar pegol in participants with neovascular age-related macular degeneration.
Official Title
Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients With Neovascular Age-related Macular Degeneration (SEQUOIA Study)
Eligibility Criteria
Ages Eligible for Study: Older than 50 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
- - Diagnosis of age-related macular degeneration in at least 1 eye - Best corrected visual acuity of 20/40 to 20/320 in the study eye - Best corrected visual acuity of 20/200 or better in the non-study eye
Exclusion Criteria:
- - History of vitrectomy, macular surgery, or glaucoma surgery in the study eye - Cataract or refractive surgery in the study eye within the last 3 months
Investigator(s)
Theodore Leng, MD, FACS
Ophthalmologist
Associate Professor of Ophthalmology and, by courtesy, of Anesthesiology, Perioperative and Pain Medicine (Adult MSD)
View on ClinicalTrials.gov
